Featured content
What tissue accumulation can reveal about oligonucleotide safety
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
ReportLab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
ArticleWhy reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
News
NewsFramework proposed to advance plant-derived anti-inflammatory drug discovery
A review led by researchers at the Naval Medical University proposes a structured framework for evaluating plant-derived anti-inflammatory compounds, warning that pathway inhibition alone is insufficient evidence of direct molecular target engagement.
NewsPSD-95 inhibition identified as therapeutic target for MEF2C haploinsufficiency
Researchers at the University of Illinois Urbana-Champaign have identified PSD-95, a synaptic scaffolding protein, as a potential therapeutic target for neurological disorders associated with loss of the autism-linked gene MEF2C.
NewsZinc finger protein found to suppress amyloid-beta aggregation in Alzheimer’s
A protein best known for regulating genes has been shown to suppress amyloid-beta aggregation and reduce aggregate toxicity in a transgenic mouse model of Alzheimer’s disease.
NewsOrganoid coculture systems offer more representative cancer research models
A new review explores how three-dimensional organoid coculture technologies could overcome the limitations of conventional cancer models, offering more physiologically relevant platforms for immunotherapy research, drug screening and personalised medicine.
From our partners
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Opinion and interviews
How multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
What it really takes to turn cancer discoveries into new therapies
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
